Pliant Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
260 Littlefield Ave, South San Francisco...Phone Number
(650) 481-6770Website
www.pliantrx.comRevenue
<$5 MillionStock Symbol
PLRXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Pliant Therapeutics
Pliant Therapeutics is a clinical stage biotechnology company targeting the key biological pathways driving fibrosis. Pliant has leveraged its powerful product discovery engine to develop a portfolio of novel therapeutics that seek to halt progression of multiple life-threatening fibrotic diseases. The company's lead product candidate, PLN-74809, is a selective inhibitor of v1 and v6 integrin receptors that play a key role in multiple fibrotic pathways. PLN-74809 has received Orphan Designation from the FDA in both idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and is being studied in an ongoing Phase 1 clinical trial. Pliant's second product candidate, PLN-1474, is a selective inhibitor of v1, targeting late-stage liver fibrosis and is currently in IND-enabling studies.Explore more
Pliant Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pliant Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if Pliant Therapeutics is spiking on competitors!
Pliant Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Pliant Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Pliant Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Pliant Therapeutics
Earning: See what the market has to say on Pliant Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Pliant Therapeutics has new funding data
Product Launch: Get notified when Pliant Therapeutics launches new products
Recommended Actions
Reach out to Masked Content who joined Pliant Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Pliant Therapeutics
Compare insights from companies similar to Pliant Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Pliant Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Pliant Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Pliant Therapeutics.
Pliant Therapeutics financials insights
Gather financial insights about Pliant Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$45M
2018
Series B
$62M
2020
Series C
$100M
Stock Offering
$144M
Pliant Therapeutics Tech Stack
A closer look at the technologies used by Pliant Therapeutics
Most Recent Scoops
Project
plans to enroll a total of 108 patients across three cohorts of 36 patients each in its Phase I-B study for PLN-101095, with initial data from the expansion cohorts anticipated starting in spring 2027.
Clinical Operations
Project
Pliant Therapeutics has initiated enrollment in its Phase I-B dose expansion study, selecting a dose of 1,000 mg twice daily corresponding to the mid-dose level from Phase I-A where efficacy signals were first observed.
Pharmaceuticals, Clinical Operations
Project
Pliant Therapeutics is advancing its skeletal muscle as the most developed tissue target, currently in non-human primate testing evaluating pharmacokinetics, pharmacodynamics, target gene knockdown, and circulating biomarkers, with an IND filing targeted for the end of 2027 to early 2028.
Research & Development, Pharmaceuticals
Project
noted that alpha-v beta-8 is constitutively expressed on T lymphocytes and activated T lymphocytes, suggesting that most patients likely have alpha-v beta-8 present in their tumor microenvironment.
Medical Research
Project
Medical Research
Pliant Therapeutics News & Media
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumorsPliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confirmed responses in checkpoint inhibitor-refractory solid tumorsPliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the 2026 RBC Capital Markets Global Healthcare Conference. Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, and Keith Cummings, M.D., Pliant’s Chief Financial Officer, will participate in a fireside chat on Tuesday, MayPliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (Nasdaq: PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. PLN-101095 is an oral, small molecule, dual selective inhibitor of the integrins αvβ8 and αvβ1.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pliant Therapeutics
Sign Up For FreeTo access detailed company insights
Pliant Therapeutics is a clinical stage biotechnology company targeting the key biological pathways driving fibrosis. Pliant has leveraged its powerful product discovery engine to develop a portfolio of novel therapeutics that seek to halt progression of multiple life-threatening fibrotic diseases. The company's lead product candidate, PLN-74809, i... Read More
